Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Targeting C3d in Combination with Daratumumab: a Strategy to Enhance Therapeutic Potential in Multiple Myeloma

Sivasubramanian Baskar, Haiyong Peng, Christoph Rader, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 9989–9990.

https://doi.org/10.1182/blood-2022-166681

Published: 2022

Journal Articles

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Deyi Zhang, PhD, Hailey Harris, Aileen Kelly, PhD, Daniel W Robbins, May Tan, Timothy Ingallinera, Neil Bence, Arthur T Sands, Sivasubramanian Baskar, Sarah E. M. Herman, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 174.

https://doi.org/10.1182/blood-2019-126921

Published: 2019

Journal Articles

Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-Cells

Maria Joao Baptista, PhD PharmD, Sivasubramanian Baskar, Keyvan Keyvanfar, Erika M Gaglione, Inhye E Ahn, MD, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3030.

https://doi.org/10.1182/blood-2019-127131

Published: 2019

Journal Articles

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

Swagata Goswami, MSc, Chi-Ling Chiang, PhD, Kevan Zapolnik, BS, Zhiliang Xie, James L. Lee, PhD, Sivasubramanian Baskar, Christoph Rader, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Bhavana Bhatnagar, DO, Natarajan Muthusamy, DVM,PhD

Blood (2019) 134 (Supplement_1): 3798.

https://doi.org/10.1182/blood-2019-128828

Published: 2019

Journal Articles

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model

Chi-Ling Chiang, Swagata Goswami, Frank W. Frissora, Zhiliang Xie, Pearlly S. Yan, Ralf Bundschuh, Logan A. Walker, Xiaomeng Huang, Rajeswaran Mani, Xiaokui M. Mo, Sivasubramanian Baskar, Christoph Rader, Mitch A. Phelps, Guido Marcucci, John C. Byrd, L. James Lee, Natarajan Muthusamy

Blood (2019) 134 (5): 432–444.

https://doi.org/10.1182/blood.2018882290

Published: 2019

Includes: Supplemental data

Journal Articles

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Hannah R. Robinson, Junpeng Qi, Erika M. Cook, Cydney Nichols, Eman L. Dadashian, Chingiz Underbayev, Sarah E. M. Herman, Nakhle S. Saba, Keyvan Keyvanfar, Clare Sun, Inhye E. Ahn, Sivasubramanian Baskar, Christoph Rader, Adrian Wiestner

Blood (2018) 132 (5): 521–532.

https://doi.org/10.1182/blood-2018-02-830992

Published: 2018

Includes: Supplemental data

Journal Articles

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

Chi-Ling Chiang, MS, Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Zhiliang Xie, Xiaomeng Huang, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, PhD, Mitch A. Phelps, PhD, Guido Marcucci, MD, John C. Byrd, MD, James L. Lee, PhD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 4981.

https://doi.org/10.1182/blood.V130.Suppl_1.4981.4981

Published: 2017

Journal Articles

Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia

Hannah R. Robinson, BA, Junpeng Qi, PhD, Sivasubramanian Baskar, PhD, Erika Cook, BA, Inhye E. Ahn, MD, Sarah E. M. Herman, PhD, Christoph Rader, PhD, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 799.

https://doi.org/10.1182/blood.V130.Suppl_1.799.799

Published: 2017

Journal Articles

Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

Chi-Ling Chiang, Frank W Frissora, Zhiliang Xie, Xiaomeng Huang, Rajeswaran Mani, DVM, Sivasubramanian Baskar, Christoph Rader, Kenneth K. Chan, Guido Marcucci, MD, John C. Byrd, MD, L. James Lee, Natarajan Muthusamy, DVM, PhD

Blood (2015) 126 (23): 1743.

https://doi.org/10.1182/blood.V126.23.1743.1743

Published: 2015

Journal Articles

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Rajeswaran Mani, DVM, Yicheng Mao, PhD, Frank W Frissora, M.S., Chi-ling Chiang, Jiang Wang, Yuan Zhao, Yun Wu, Bo Yu, Ph.D., Ribai Yan, Xiaokui Mo, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, Ph.D., Mitch A. Phelps, PhD, Robert J. Lee, Ph.D, Ching-Shih Chen, PhD, James Lee, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2013) 122 (21): 4168.

https://doi.org/10.1182/blood.V122.21.4168.4168

Published: 2013

Journal Articles

Generation of a Platform for Identification of CLL Specific Cell Surface Proteins Targeted by Anti-Tumor Antibodies in Patient Sera After Allogeneic Hematopoietic Cell Transplantion

Brian C Shaffer, MD, Judith Leitner, PhD, Adrian Wiestner, MD, PhD, Michael R. Bishop, MD, Steven Z. Pavletic, MD, Ronald E. Gress, MD, Peter Steinberger, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, Ph.D.

Blood (2012) 120 (21): 1349.

https://doi.org/10.1182/blood.V120.21.1349.1349

Published: 2012

Journal Articles

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

Davide Bagnara, Matthew S. Kaufman, Carlo Calissano, Sonia Marsilio, Piers E. M. Patten, Rita Simone, Philip Chum, Xiao-Jie Yan, Steven L. Allen, Jonathan E. Kolitz, Sivasubramanian Baskar, Christoph Rader, Hakan Mellstedt, Hodjattallah Rabbani, Annette Lee, Peter K. Gregersen, Kanti R. Rai, Nicholas Chiorazzi

Blood (2011) 117 (20): 5463–5472.

https://doi.org/10.1182/blood-2010-12-324210

Published: 2011

Includes: Supplemental data

Journal Articles

The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor

Michael Hudecek, Thomas M. Schmitt, Sivasubramanian Baskar, Maria Teresa Lupo-Stanghellini, Tetsuya Nishida, Tori N. Yamamoto, Marie Bleakley, Cameron J. Turtle, Wen-Chung Chang, Harvey A. Greisman, Brent Wood, David G. Maloney, Michael C. Jensen, Christoph Rader, Stanley R. Riddell

Blood (2010) 116 (22): 4532–4541.

https://doi.org/10.1182/blood-2010-05-283309

Published: 2010

Includes: Supplemental data

Journal Articles

CD8 + T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor Specifically Recognize ROR1 Positive B Cell Tumors.

Michael Hudecek, MD, Thomas M Schmitt, PhD, Sivasubramanian Baskar, PhD, Wen-Chung Chang, David G Maloney, MD, PhD, Michael C Jensen, M.D., Christoph M. Rader, Ph.D., Stanley Riddell, MD

Blood (2009) 114 (22): 930.

https://doi.org/10.1182/blood.V114.22.930.930

Published: 2009

Journal Articles

A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display

Sivasubramanian Baskar, Jessica M. Suschak, Ivan Samija, Ramaprasad Srinivasan, Richard W. Childs, Steven Z. Pavletic, Michael R. Bishop, Christoph Rader

Blood (2009) 114 (20): 4494–4502.

https://doi.org/10.1182/blood-2009-05-222786

Published: 2009

Journal Articles

Elevated BAFF Is Correlated with Inflammatory Processes in Chronic Graft Versus Host Disease and Supports Increases in Transitional B Cells

Frances T. Hakim, PhD, Najibah Rehman, John Dickinson, MD, Sivasubramanian Baskar, PhD, Christoph M. Rader, PhD, Edward W. Cowen, MD, Steven Z. Pavletic, MD, Ronald E. Gress, MD

Blood (2008) 112 (11): 465.

https://doi.org/10.1182/blood.V112.11.465.465

Published: 2008

Journal Articles

Soluble BAFF Is Elevated Following Allogeneic SCT but Is Not an Early Predictor for the Development of cGVHD.

John D. Dickinson, MD, PhD, Iskra Pusic, MD, Christoph Rader, PhD, Seth Steinberg, PhD, Fran Hakim, PhD, Sivasubramanian Baskar, PhD, Steven Z. Pavletic, MD

Blood (2007) 110 (11): 167.

https://doi.org/10.1182/blood.V110.11.167.167

Published: 2007

Journal Articles

Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo

Arya Biragyn, Pier Adelchi Ruffini, Marta Coscia, Linda K. Harvey, Sattva S. Neelapu, Sivasubramanian Baskar, Ji-Ming Wang, Larry W. Kwak

Blood (2004) 104 (7): 1961–1969.

https://doi.org/10.1182/blood-2004-02-0637

Published: 2004

NARROW

Targeting C3d in Combination with Daratumumab: a Strategy to Enhance Therapeutic Potential in Multiple Myeloma

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-Cells

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia

Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Generation of a Platform for Identification of CLL Specific Cell Surface Proteins Targeted by Anti-Tumor Antibodies in Patient Sera After Allogeneic Hematopoietic Cell Transplantion

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor

CD8 + T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor Specifically Recognize ROR1 Positive B Cell Tumors.

A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display

Elevated BAFF Is Correlated with Inflammatory Processes in Chronic Graft Versus Host Disease and Supports Increases in Transitional B Cells

Soluble BAFF Is Elevated Following Allogeneic SCT but Is Not an Early Predictor for the Development of cGVHD.

Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only